Dofixim40 mg/5 ml

Dofixim is an oral third-generation cephalosporin antibiotic used to treat infections caused by susceptible bacteria. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Acute otitis media (middle ear infection) in susceptible patients
• Pharyngitis and tonsillitis caused by Streptococcus pyogenes
• Acute maxillary sinusitis
• Community-acquired pneumonia (mild to moderate)
• Acute bacterial exacerbation of chronic bronchitis
• Uncomplicated skin and skin-structure infections
• Uncomplicated urinary tract infections (cystitis)
• Uncomplicated gonorrhea (cervical/urethral) and rectal gonococcal infection in women

Guideline-supported / commonly used off-label

• As an alternative oral step-down agent for certain susceptible respiratory tract infections when guided by culture and susceptibility results

Dofixim should only be used for infections proven or strongly suspected to be caused by susceptible bacteria; it is not effective against viral infections such as the common cold or flu.

Each formulation of Cefpodoxime Proxetil contains cefpodoxime proxetil, an ester prodrug of the active antibiotic cefpodoxime, as the active pharmaceutical ingredient.

• Tablet: commonly available as 100 mg and 200 mg film-coated tablets
• Powder for oral suspension: commonly available as 40 mg/5 mL and 80 mg/5 mL after reconstitution

Exact strengths and available brand formulations may vary by manufacturer and country; consult local product labeling for confirmation.

Dofixim is a semi-synthetic, orally administered, extended-spectrum cephalosporin antibiotic belonging to the third generation of the cephalosporin class. It is a prodrug that is hydrolyzed in the intestinal mucosa to its active form, cefpodoxime, which exerts bactericidal activity against a broad range of gram-positive and gram-negative organisms.

Dofixim is used to treat mild to moderate bacterial infections of the respiratory tract, skin, urinary tract, and certain sexually transmitted infections, in adults and children as appropriate for the specific indication.

Third-generation oral cephalosporin antibiotic. Dofixim belongs to this class of beta-lactam antibacterial agents.

Cefpodoxime Proxetil is an ester prodrug that, after oral administration, is de-esterified during absorption to release the active moiety, cefpodoxime.

Mechanism

Cefpodoxime exerts bactericidal activity by binding to penicillin-binding proteins (PBPs), thereby inhibiting bacterial cell wall (peptidoglycan) synthesis, which leads to cell lysis and death.

Spectrum

Cefpodoxime Proxetil demonstrates activity against many gram-positive organisms (e.g., Streptococcus pneumoniae, Streptococcus pyogenes) and gram-negative organisms (e.g., Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Neisseria gonorrhoeae), and has good stability against many bacterial beta-lactamase enzymes.

Pharmacokinetics

Absorption of Cefpodoxime Proxetil is enhanced by food; peak plasma concentrations of active cefpodoxime are reached approximately 2-3 hours after dosing. Approximately 29-33% of the absorbed dose is excreted unchanged in the urine within 12 hours, and the drug is eliminated mainly by renal mechanisms, so dosing interval adjustment is needed in significant renal impairment.

Dofixim tablets should be taken with food to enhance absorption and improve tolerability; the oral suspension may be taken with or without food.

• Swallow tablets whole; do not crush or chew unless directed by a physician.
• Shake the oral suspension well before each use and measure doses with an accurate measuring device.
• Take doses at evenly spaced intervals (approximately every 12 hours) to maintain consistent drug levels.
• Complete the full prescribed course even if symptoms improve before finishing the medicine.
• If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.

Do not stop, extend, skip doses, or share Dofixim with others without medical advice.

Dofixim has the following well-documented, clinically significant interactions:

• Antacids, H2-receptor blockers, and proton pump inhibitors: These agents raise gastric pH and can reduce absorption of Dofixim by roughly a quarter to a third, lowering its effectiveness. If concurrent use is necessary, Dofixim should be taken at least 2 hours before or after these agents, or dosing spaced as advised by a physician.
• Probenecid: Co-administration inhibits renal tubular secretion of cefpodoxime, increasing its plasma concentration and half-life by approximately 30%; dose adjustment or monitoring may be needed.
• Nephrotoxic drugs (e.g., aminoglycosides, potent loop diuretics): Concurrent use with Dofixim may increase the risk of kidney impairment; renal function should be monitored.

Always inform your physician or pharmacist about all medicines, supplements, and antacids you are taking before starting Dofixim.

As with other cephalosporin antibiotics, Dofixim can cause side effects, most of which are mild and self-limiting.

Common side effects

• Diarrhea (most common)
• Nausea and abdominal pain
• Headache and dizziness
• Vaginal fungal infection (vulvovaginal candidiasis)

Less common but serious side effects

• Clostridioides difficile-associated diarrhea/pseudomembranous colitis, which can range from mild to life-threatening
• Severe hypersensitivity reactions, including anaphylaxis and Stevens-Johnson syndrome/toxic epidermal necrolysis
• Serum sickness-like reactions

Seek prompt medical attention for severe or persistent diarrhea, signs of an allergic reaction (rash, swelling, difficulty breathing), or any severe skin reaction while taking Dofixim.

Pregnancy: Animal reproduction studies with Dofixim have not shown evidence of harm to the fetus; however, adequate and well-controlled studies in pregnant women are lacking. Dofixim should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Cefpodoxime is excreted in human breast milk in small amounts. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Dofixim, taking into account the importance of the drug to the mother and possible effects on the nursing infant.

Cross-reactivity with penicillin allergy: Patients with a history of penicillin allergy may also be allergic to Dofixim; use with caution and monitor closely in such patients, as cross-reactivity among beta-lactam antibiotics can occur.

Clostridioides difficile-associated diarrhea: As with nearly all antibacterial agents, Dofixim can lead to overgrowth of C. difficile, ranging from mild diarrhea to fatal colitis. Evaluate patients who develop diarrhea during or after treatment.

Reduced absorption with acid-reducing agents: Concomitant use of antacids, H2-blockers, or proton pump inhibitors can significantly reduce absorption of Dofixim; see Interactions for spacing recommendations.

Renal impairment: Dose interval adjustment is required in severe renal impairment (see Dosage and Administration).

Superinfection: Prolonged use of Dofixim may result in overgrowth of non-susceptible organisms, including fungi; monitor for signs of superinfection during prolonged therapy.

Antibiotic stewardship: Take Dofixim exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is limited clinical experience with Dofixim overdosage. Symptoms of overdose may be expected to be extensions of common adverse effects, primarily gastrointestinal (nausea, vomiting, diarrhea, abdominal discomfort).

In case of a suspected overdose of Dofixim, seek immediate medical attention or contact a poison control center/emergency services right away. Hemodialysis or peritoneal dialysis may help remove cefpodoxime from the body in patients with impaired renal function; treatment is otherwise general and supportive, guided by a physician. Do not attempt specific home treatment without medical advice.

Store Dofixim tablets at room temperature (below 30°C), away from light and moisture. If dispensed as a powder for oral suspension, reconstituted Dofixim suspension should be stored in a refrigerator (2-8°C) and discarded after 14 days if unused, or as directed on the label. Keep out of reach of children.

Pediatric use: Dofixim is approved for use in infants and children 2 months of age and older for specific indications, generally dosed at approximately 5 mg/kg every 12 hours; safety and efficacy have not been established in infants younger than 2 months.

Elderly: No dose adjustment is generally required in elderly patients with normal renal function; renal function should be assessed, since dose interval adjustment is needed with significant renal impairment (see Dosage and Administration).

Renal impairment: Dosing interval should be extended to every 24 hours in patients with creatinine clearance less than 30 mL/min.

Hepatic impairment: No specific dose adjustment has been well established; use with routine clinical monitoring.

Pregnancy and lactation: See Pregnancy and Lactation section above.

The duration of treatment with Dofixim depends on the infection being treated, and typically ranges from a single dose (for uncomplicated gonorrhea) to 5-14 days for other infections, as outlined in Dosage and Administration. The full prescribed course should always be completed, even if symptoms resolve earlier, to reduce the risk of relapse and antibiotic resistance. Do not extend treatment beyond what is prescribed without consulting a physician.

For the powder-for-oral-suspension formulation of Dofixim, reconstitute by adding the specified amount of water (as indicated on the bottle label) to the dry powder in two portions, shaking well after each addition, to produce the labeled concentration (e.g., 40 mg/5 mL or 80 mg/5 mL).

Once reconstituted, store the suspension in a refrigerator and shake well before each use. Discard any unused suspension after 14 days. Always follow the specific reconstitution instructions printed on the product label, as these can vary by manufacturer.

Cephalosporins (third-generation, oral); Beta-lactam antibacterial agents

Cefpodoxime Proxetil is a prodrug that is hydrolyzed during intestinal absorption to its active form, cefpodoxime. Cefpodoxime binds to penicillin-binding proteins (PBPs) located on the bacterial cell membrane, inhibiting the final transpeptidation step of bacterial cell wall (peptidoglycan) synthesis. This disruption weakens the cell wall, causing bacterial cell lysis and death (bactericidal action). Cefpodoxime Proxetil's activity is enhanced by its relative stability against many common bacterial beta-lactamase enzymes.

B

Dofixim is approved for use in pediatric patients 2 months of age and older for specific approved indications (e.g., acute otitis media, pharyngitis/tonsillitis, acute maxillary sinusitis), typically dosed at approximately 5 mg/kg body weight every 12 hours, not exceeding the maximum adult dose for the indication.

Safety and efficacy of Dofixim have not been established in infants younger than 2 months of age. Fungal skin rash and diaper-area candidiasis have been reported somewhat more frequently in children than adults; monitor pediatric patients accordingly during therapy.